Clinical Trials

1,264 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03829332 2026-02-19

LEAP-007

623 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06780085 2026-02-19

MK-3475-01H

Phase 2 Recruiting

96 enrolled

Phase 2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03076554 2026-01-08

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

56 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Thymoma

NCT05609968 2025-12-24

MK-3475-D46

614 enrolled

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06049212 2025-12-19

TroFuse-008

30 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03924869 2025-12-11

KEYNOTE-867

Phase 3 Terminated

448 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04165083 2025-11-26

MK-3475-01B

102 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04995523 2025-11-24

ARTEMIDE-01

Phase 1/2 Recruiting

210 enrolled

GastrointestinalHead & NeckSarcomaThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Phase 1 Terminated

122 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT02628067 2025-09-22

KEYNOTE 158

Phase 2 Active not recruiting

1,609 enrolled 5 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03715205 2025-08-29

Keynote-593

Phase 4 Completed

150 enrolled 14 charts

DermatologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04458259 2025-08-28

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Phase 1 Terminated

88 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT03322540 2025-08-22

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

154 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04380636 2025-08-17

MK-7339-012

870 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02903914 2025-08-05

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

GastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

260 enrolled 52 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

NCT05298423 2025-08-01

KEYVIBE-006

611 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04924101 2025-07-23

KEYNOTE-B99

126 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT04153565 2025-07-17

MK-3475-A17

Other solid neoplasmThoracic

19 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma

NCT04624204 2025-07-02

MK 7339-013

672 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT04165096 2025-06-25

MK-3475-01C

128 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04676412 2025-04-04

LEAP-007

107 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03631784 2025-03-25

KEYNOTE-799

216 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04956692 2024-12-03

MK-3475-A86

531 enrolled 18 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02775435 2024-10-08

KEYNOTE-407

559 enrolled 18 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03875092 2024-10-01

KEYNOTE-407

125 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02864394 2024-09-19

MK-3475-033

425 enrolled 25 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03664024 2024-08-22

KEYNOTE-782

118 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT03950674 2024-06-10

MK-3475-189

40 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05709821 2024-04-24

IMM60 and Pembrolizumab in Melanoma and NSCLC

Phase 1/2 Terminated

1 enrolled

DermatologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04271384 2023-12-26

Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer

25 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03302234 2023-09-26

KEYNOTE-598

568 enrolled 20 charts

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02835690 2022-10-26

MK-3475-032

44 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03066778 2022-10-03

KEYNOTE-604

453 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT05505877 2022-08-18

Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors

Phase 1/2 Unknown

160 enrolled

Head & NeckThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT04749394 2022-08-16

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

Phase 2 Unknown

42 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

Phase 2 Unknown

52 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT03322566 2022-01-24

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

233 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02403193 2022-01-12

AdenONCO

92 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT01905657 2021-10-06

MK-3475-010

Phase 2/3 Completed

1,034 enrolled 16 charts